Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.
De Gassart A, Le KS, Brune P, Agaugué S, Sims J, Goubard A, Castellano R, Joalland N, Scotet E, Collette Y, Valentin E, Ghigo C, Pasero C, Colazet M, Guillén J, Cano CE, Marabelle A, De Bonno J, Hoet R, Truneh A, Olive D, Frohna P. De Gassart A, et al. Among authors: goubard a. Sci Transl Med. 2021 Oct 20;13(616):eabj0835. doi: 10.1126/scitranslmed.abj0835. Epub 2021 Oct 20. Sci Transl Med. 2021. PMID: 34669444
CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer.
Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Levêque J, Jézéquel P, Campion L, Campone M, Ducret T, MacGrogan G, Debure L, Collette Y, Vacher P, Legembre P. Malleter M, et al. Among authors: goubard a. Cancer Res. 2013 Nov 15;73(22):6711-21. doi: 10.1158/0008-5472.CAN-13-1794. Epub 2013 Sep 26. Cancer Res. 2013. PMID: 24072745
Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.
De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Françoijs KJ, Ablain J, Valente S, Castellano R, Goubard A, Collette Y, Mandoli A, Martens JH, de Thé H, Nebbioso A, Mai A, Stunnenberg HG, Altucci L. De Bellis F, et al. Among authors: goubard a. Cancer Res. 2014 Apr 15;74(8):2328-39. doi: 10.1158/0008-5472.CAN-13-2568. Epub 2014 Feb 24. Cancer Res. 2014. PMID: 24566867
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL.
Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, Payet-Bornet D. Loosveld M, et al. Among authors: goubard a. Oncotarget. 2014 May 30;5(10):3168-72. doi: 10.18632/oncotarget.1873. Oncotarget. 2014. PMID: 24930440 Free PMC article.
Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.
Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N. Collette Y, et al. Among authors: goubard a. Blood Cancer J. 2015 Mar 13;5(3):e292. doi: 10.1038/bcj.2015.13. Blood Cancer J. 2015. PMID: 25768406 Free PMC article. No abstract available.
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D. Le Roy A, et al. Among authors: goubard a. Front Immunol. 2018 May 4;9:977. doi: 10.3389/fimmu.2018.00977. eCollection 2018. Front Immunol. 2018. PMID: 29780393 Free PMC article.
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.
Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D, Nunès JA. Karkeni E, et al. Among authors: goubard a. Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019. Front Immunol. 2019. PMID: 31244851 Free PMC article.
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells.
Amatore F, Ortonne N, Lopez M, Orlanducci F, Castellano R, Ingen-Housz-Oro S, De Croos A, Salvado C, Gorvel L, Goubard A, Collette Y, Bouabdallah R, Schiano JM, Bonnet N, Grob JJ, Gaulard P, Bagot M, Bensussan A, Berbis P, Olive D. Amatore F, et al. Among authors: goubard a. Blood Adv. 2020 Oct 27;4(20):5203-5214. doi: 10.1182/bloodadvances.2020002395. Blood Adv. 2020. PMID: 33095875 Free PMC article.
43 results